In summary, our study identifies Tregs as central regulators of immune escape of LSCs and identifies TNFRSF4 as a potential target to modulate the Tregs and promote antileukemic immunity in CML. This evidence concerns the gene TNFRSF4 and chronic myelogenous leukemia, BCR-ABL1 positive.